AAAAAA

   
Results: 1-7 |
Results: 7
Replacing ritonavir by nelfinavir or nelfinavir/saquinavir as part of highly active antiretroviral therapy leads to an improvement of triglyceride levels
Authors: Wensing, AMJ Reedijk, M Richter, C Boucher, CAB Borleffs, JCC
Citation: Amj. Wensing et al., Replacing ritonavir by nelfinavir or nelfinavir/saquinavir as part of highly active antiretroviral therapy leads to an improvement of triglyceride levels, AIDS, 15(16), 2001, pp. 2191-2193
The dominant source of CD4(+) and CD8(+) T-cell activation in HIV infection is antigenic stimulation
Authors: Stuart, JWTC Hazebergh, MD Hamann, D Otto, SA Borleffs, JCC Miedema, F Boucher, CAB de Boer, RJ
Citation: Jwtc. Stuart et al., The dominant source of CD4(+) and CD8(+) T-cell activation in HIV infection is antigenic stimulation, J ACQ IMM D, 25(3), 2000, pp. 203-211
Increased cell division but not thymic dysfunction rapidly affects the T-cell receptor excision circle content of the naive T cell population in HIV-1 infection
Authors: Hazenberg, MD Otto, SA Stuart, JWTC Verschuren, MCM Borleffs, JCC Boucher, CAB Coutinho, RA Lange, JMA De Wit, TFR Tsegaye, A Van Dongen, JJM Hamann, D De Boer, RJ Miedema, F
Citation: Md. Hazenberg et al., Increased cell division but not thymic dysfunction rapidly affects the T-cell receptor excision circle content of the naive T cell population in HIV-1 infection, NAT MED, 6(9), 2000, pp. 1036-1042
T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART)
Authors: Hazenberg, MD Stuart, JWTC Otto, SA Borleffs, JCC Boucher, CAB de Boer, RJ Miedema, F Hamann, D
Citation: Md. Hazenberg et al., T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART), BLOOD, 95(1), 2000, pp. 249-255
Efficacy and safety of combination therapy with delavirdine and zidovudine: a European/Australian phase II trial
Authors: Been-Tiktak, AMM Boucher, CAB Brun-Vezinet, F Joly, V Mulder, JW Jost, J Cooper, DA Moroni, M Gatell, JM Staszewski, S Colebunders, R Stewart, GJ Hawkins, DA Johnson, MA Parkin, JM Kennedy, DH Hoy, JF Borleffs, JCC
Citation: Amm. Been-tiktak et al., Efficacy and safety of combination therapy with delavirdine and zidovudine: a European/Australian phase II trial, INT J ANT A, 11(1), 1999, pp. 13-21
Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study)
Authors: Stuart, JWTC Schuurman, R Burger, DM Koopmans, PP Sprengers, HG Juttmann, JR Richter, C Meenhorst, PL Hoetelmans, RMW Kroon, FP Bravenboer, B Hamann, D Boucher, CAB Borleffs, JCC
Citation: Jwtc. Stuart et al., Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study), AIDS, 13(7), 1999, pp. F53-F58
Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy
Authors: Schneider, MME Borleffs, JCC Stolk, RP Jaspers, CAJJ Hoepelman, AIM
Citation: Mme. Schneider et al., Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy, LANCET, 353(9148), 1999, pp. 201-203
Risultati: 1-7 |